Beijing Beilu Pharmaceutical Company Limited operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Beijing Beilu Pharmaceutical Company Limited with three other
companies in this sector in China:
Sinovac Biotech Ltd
sales of 481.91 million Chinese Renmimbi [US$74.60 million]
of which 49%
was Enterovirus 71 vaccines),
Furen Pharmaceutical Group Industry Co Ltd
(495.63 million Chinese Renmimbi [US$76.72 million]
of which 95%
was Pharmaceutical Industry), and
Lionco Pharmaceutical Group Co Ltd
(478.59 million Chinese Renmimbi [US$74.09 million]
of which 100%
Beijing Beilu Pharmaceutical Company Limited reported sales of 498.81 million Chinese Renmimbi (US$77.22 million)
December of 2016.
increase of 2.1%
versus 2015, when the company's sales were 488.61 million Chinese Renmimbi.
Sales at Beijing Beilu Pharmaceutical Company Limited have increased during each of the previous five years
(and since 2011, sales have increased a total of 154%).
Sales of Other Operation saw an increase
that was more than double the company's growth rate: sales were up
72.3% in 2016, from
2.76 million Chinese Renmimbi to 4.75 million Chinese Renmimbi.
Beijing Beilu Pharmaceutical Company Limited also saw significant increases in sales in
Pharmaceutical Sales (up 11.3% to 469.91 million Chinese Renmimbi)
Not all segments of Beijing Beilu Pharmaceutical Company Limited experienced an increase in sales in 2016:
sales of Cell Medical Treatment fell 63.6% to 24.20 million Chinese Renmimbi.